Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 318.93B +71.3% |
| Revenue (ttm) | 59.33B +4.9% |
| Net Income | 2.16B -87.1% |
| EPS | 0.88 -86.9% |
| Shares Out | n/a |
| PE Ratio | 147.73 |
| Forward PE | 17.20 |
| Dividend | 2.94 (2.26%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 841 |
| Open | 128.30 |
| Previous Close | 129.86 |
| Day's Range | 128.30 - 130.08 |
| 52-Week Range | 71.40 - 136.44 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
The US Food and Drug Administration on Tuesday issued an emergency use authorization for Merck's Bravecto tablets to treat New World screwworm in dogs and puppies, expanding treatment options to com...
Merck initiates Phase 3 study of Ohtuvayre
Merck (MRK) announced the initiation of ENHANCE-3, a Phase 3 randomized clinical trial evaluating Ohtuvayre (ensifentrine) for the prevention of chronic obstructive pulmonary disease exacerbations in ...
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized ...
Merck downgraded to Hold from Buy at DZ Bank
DZ Bank analyst Elmar Kraus downgraded Merck (MRK) to Hold from Buy with a $153 price target
Merck price target raised to $140 from $125 at Freedom Broker
Freedom Broker raised the firm’s price target on Merck (MRK) to $140 from $125 and keeps a Hold rating on the shares. The firm raised its valuation multiple with investors…
Merck price target raised to $155 from $145 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Merck (MRK) to $155 from $145 and keeps a Neutral rating on the shares. Merck delivered a solid ESMO showing and better-than-expected…
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
Moderna, Merck eye FDA approval for promising cancer vaccine
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.'
Merck price target lowered to $174 from $177 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Merck (MRK) to $174 from $177 and keeps an Overweight rating on the shares.
Merck price target raised to $175 from $165 at JPMorgan
JPMorgan raised the firm’s price target on Merck (MRK) to $175 from $165 and keeps an Overweight rating on the shares.
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today re...
Merck price target raised to $171 from $170 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $171 from $170 and keeps a Buy rating on the shares after updating the firm’s model following the company’s Q3…
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is inve...
Merck & Co. Earnings Call Transcript: Q3 2026
Q3 revenue rose 5% to $18.1B, with new products and oncology and animal health strength. 2026 guidance midpoint increased; 2027 is expected to bring moderate growth amid >$2B of generic and LOE headwinds and continued investment.
Merck & Co. Earnings release: Q3 2026
Merck & Co. released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Merck & Co. Prepared remarks: Q3 2026
Merck & Co. filed a regulatory document on October 29, 2026 disclosing important business information.
Merck & Co. Slides: Q3 2026
Merck & Co. has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Merck Stock (MRK) Rises 2% on $830 Million Keytruda Sales Beat, Q3 Forecasts, and Higher Full-Year Profit Outlook
Merck & Co ($MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted profit forecast. Strong demand for its…
Merck Revenue Up on Keytruda, Winrevair Growth
Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expect...
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.
Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline.
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Merck & Co. Transcript: Investor update
TroFuse-005 showed significant PFS, OS and response gains for sac-TMT in advanced or recurrent endometrial cancer. INTerpath-001 delivered positive phase III results for individualized neoantigen therapy in melanoma, while MK-2010 phase III studies are anticipated in H1 2027.
Merck & Co. Slides: Investor update
Merck & Co. has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.